Prostate Cancer - Results from #23980

GU Cancers Symposium 2013 - Differential effects of galeterone, abiraterone, orteronel, and ketoconazole on CYP17 and steroidogenesis, by Douglas B. Jacoby, et al. - Session Highlights February 26, 2013

GU Cancers Symposium 2013 - A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer - Session Highlights February 26, 2013

GU Cancers Symposium 2013 - Effect of PSA-TRICOM, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa, by James L. Gulley, et al. - Session Highlights February 25, 2013

GU Cancers Symposium 2013 - The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study, by Robert van Soest, et al. - Session Highlights February 25, 2013

From "magic bullets" to specific cancer immunotherapy - Abstract February 25, 2013

Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer - Abstract February 25, 2013

Validation of the prognostic grouping of the seventh edition of the tumor-nodes-metastasis classification using a large-scale prospective cohort study database of prostate cancer treated with primary androgen deprivation therapy - Abstract February 25, 2013

Contrast-enhanced ultrasound as support for prostate brachytherapy treatment planning - Abstract February 25, 2013

'Living under assault': Men making sense of cancer - Abstract February 25, 2013

Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer - Abstract February 25, 2013

GU Cancers Symposium 2013 - Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis, by Jessica Strock, et al. - Session Highlights February 25, 2013

GU Cancers Symposium 2013 - Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer, by Bertrand Tombal, MD, PhD, et al. - Session Highlights February 25, 2013

Androgen receptor antagonists in castration-resistant prostate cancer - Abstract February 25, 2013

Benefits of a dual sagittal crystal transducer for ultrasound imaging during I-125 seed implantation for permanent prostate brachytherapy - Abstract February 25, 2013

GU Cancers Symposium 2013 - Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in patients with biochemically-recurrent prostate cancer, by Emmanuel S. Antonarakis, MD, et al. - Session Highlights February 23, 2013

Potentials and limitations of real-time elastography for prostate cancer detection: A whole-mount step section analysis - Abstract February 22, 2013

Long-term tumor control after brachytherapy for base-of-prostate cancer - Abstract February 22, 2013

Progressive transition from pre-planned to intraoperative optimizing seed implant: Post implementation analysis - Abstract February 22, 2013

The role of targeted focal therapy in the management of low-risk prostate cancer: Update on current challenges - Abstract February 22, 2013

Treatment of locally advanced prostate cancer: A case report and narrative review - Abstract February 22, 2013

Page 1200 of 1447